MedTrace Logo

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

NCT02531932 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-02-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared to the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC).

Study close to accrual

Conditions

Interventions

DRUG

Carboplatin

Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k

DRUG

Everolimus

The study drug Everolimus will be self-administered (by the patients themselves).

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Amy Tiersten

    lead OTHER

Principal Investigators

  • Amy Tiersten, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-16
Primary Completion
2024-09-30
Completion
2024-10-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02531932 on ClinicalTrials.gov